echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > India's biggest drugmaker has been fined $500 million for drug adulteration in the US

    India's biggest drugmaker has been fined $500 million for drug adulteration in the US

    • Last Update: 2013-05-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2013-05-15 source: Legal Evening News reported this morning that India's largest pharmaceutical company, Nanxin, was fined a record $500 million in the United States for selling adulterated drugs and attempting to deceive regulators Drug adulteration report fraud US regulators launched a one-year investigation into the production defects of Nanxin company The U.S Food and Drug Administration (FDA) has previously banned the company from importing 30 drugs from India FDA also reached an agreement with the company to require the company to provide accurate product information and improve its drug manufacturing process Nanxin admitted that it had manufactured and sold adulterated drugs, the report said The prosecutor pointed out that among the batches of adulterated drugs found, the strength, purity and quality of the drugs did not conform to the marked specifications These include generic antibiotics and other drugs used to treat severe nodular acne, epilepsy and neuralgia According to the report, it is not clear whether the drugs involved will cause health problems In addition, the company also acknowledged the improper storage of drug samples, the sale of drugs that did not pass the purity test, and the delayed recall of expired drugs for several months The company also acknowledged that the test reports submitted to the US FDA in 2006 and 2007 were false in time The $500 million company said it was "fully cooperating" with the investigation, agreeing on Monday to pay a $150 million fine and confiscation of property, as well as $350 million to settle civil litigation over the issue Alan, CEO of Nanxin company In a statement, Sonne said: 'we are disappointed with our past actions and believe that the final settlement of this matter is in the interests of all shareholders The result of the judgment does not seriously affect the company's current financial situation and operation Prosecutors said the penalty for Nanxin was the largest for similar pharmaceutical companies The company is in violation of the federal food, drug, and Cosmetic Act, which prohibits the sale of drugs of insufficient purity in the United States "Deep throat" reported the east window incident According to reports, a reporter reported the above behavior of Nanxin company to the FDA, so the regulatory authorities began to investigate Later, it was revealed that the whistleblower was Denise, a former executive of the company Thakur Reported that due to the merits of the report, takur will receive a reward of $49 million Takur said in a statement that the company had been told there was a problem, but could not deal with it properly, so it had "no choice" but to inform the relevant health regulatory authorities Takur's lawyer said that as the most original source of information about the incident, takur's information eventually led to timely action by the government  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.